Results 11 to 20 of about 93,898 (384)

Benralizumab in severe eosinophilic asthma

Signa Vitae

semanticscholar   +3 more sources

Eosinophilic bioactivities in severe asthma [PDF]

World Allergy Organization Journal, 2016
Asthma is clearly related to airway or blood eosinophilia, and asthmatics with significant eosinophilia are at higher risk for more severe disease. Eosinophils actively contribute to innate and adaptive immune responses and inflammatory cascades through ...
Tara F. Carr, Sergejs Berdnikovs, Hans-Uwe Simon, Bruce S. Bochner, Lanny J. Rosenwasser   +4 more
doaj   +4 more sources

Efficacy of Benralizumab in Reducing FeNO in Severe Eosinophilic Asthma: The Role of CRSwNP [PDF]

Journal of Asthma and Allergy
Juan Luis Garcia-Rivero,1,2 Beatriz Abascal-Bolado,1 Nieves Aranda Sobrino,2 Cristina Ghadban Garrido2 1Respiratory Department, Marqués de Valdecilla University Hospital, Santander, Spain; 2Valdecilla Research Institute (IDIVAL), Santander ...
Garcia-Rivero JL, Abascal-Bolado B, Aranda Sobrino N, Ghadban Garrido C   +3 more
doaj   +1 more source

Anti-interleukin-5/anti-interleukin-5 receptor α treatment improves self-reported work productivity in patients with severe eosinophilic asthma: a prospective cohort trial [PDF]

ERJ Open Research
Background Severe asthma affects the working life of millions of people worldwide. Interleukin (IL)-5/anti-interleukin-5 receptor α (IL-5Rα) antibodies are highly effective in reducing symptoms in patients with severe eosinophilic asthma.
Lina Brinkmann, Jan Fuge, Tobias Welte, Hendrik Suhling, Nora Drick   +4 more
doaj   +2 more sources

Mepolizumab treatment in patients with severe eosinophilic asthma. [PDF]

New England Journal of Medicine, 2014
Some patients with severe asthma have frequent exacerbations associated with persistent eosinophilic inflammation despite continuous treatment with high-dose inhaled glucocorticoids with or without oral glucocorticoids.In this randomized, double-blind, double-dummy study, we assigned 576 patients with recurrent asthma exacerbations and evidence of ...
Hector G Ortega, Mark C Liu, I. Pavord, Guy Brusselle, J. Fitzgerald, A. Chetta, M. Humbert, Lynn E Katz, Oliver N. Keene, Steven W. Yancey, P. Chanez, Nc Park, S. W. Y. Johns, Italy, Assistance Publique, Le Kremlin-Bicêtre   +15 more
semanticscholar   +4 more sources

Challenges With the Intolerance of Biologics in Severe Eosinophilic Asthma: The Risk of Exacerbations Is Time-Dependent With the Rise of Eosinophils. [PDF]

Cureus
Cortes-Telles A, Pou-Aguilar YN, Figueroa-Hurtado E, Vazquez-Lopez S, Ortiz DL.   +4 more
europepmc   +3 more sources

Construction of Severe Eosinophilic Asthma Related Competing Endogenous RNA Network by Weighted Gene Co-Expression Network Analysis

Frontiers in Pharmacology, 2022
Background: Currently, disease control in patients with severe eosinophilic asthma is not optimistic. Competing endogenous RNA (ceRNA) networks have been found to play a key role in asthma in recent years.
Haixia Wang, Zeyi Zhang, Yu Ma, Yuanmin Jia, Bin Ma, Junlian Gu, Ou Chen, Ou Chen, Shouwei Yue, Shouwei Yue   +9 more
doaj   +1 more source

Two years follow-up of relapsing eosinophilic pneumonia with concomitant severe asthma successfully treated with benralizumab: A case report and brief review of the literature

Respiratory Medicine Case Reports, 2023
Relapsing eosinophilic pneumonia and severe eosinophilic asthma are rare and disabling diseases, which share common inflammatory backgrounds and often require long-term systemic steroid therapy.
G. Angeletti, M. Mazzolini, A. Rocca
doaj   +1 more source

Primary care of asthma: new options for severe eosinophilic asthma [PDF]

Current Medical Research and Opinion, 2019
Objective: Asthma is a common heterogeneous disease characterized by airway inflammation and bronchoconstriction. Current treatment guidelines provide recommendations for categorizing disease severity, asthma control and management. This paper reviews asthma assessment in primary care and describes the pathophysiology, clinical characteristics and new ...
NEIL SKOLNIK, Sean P. Carnahan
openalex   +3 more sources

IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma. [PDF]

Mucosal Immunol
Luo J, Chen W, Liu W, Jiang S, Ye Y, Shrimanker R, Hynes G, Klenerman P, Pavord ID, Xue L.   +9 more
europepmc   +2 more sources